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Outcomes of In-Hospital Cardiopulmonary Resuscitation for
Cardiac Arrest in Adult Patients With Metastatic Solid Cancers:
A Nationwide Inpatient Sample Database Analysis From 2012 to
2014
Sindhu Malapati, MD

1

; Sunny R. K. Singh, MD2; Rohit Kumar, MD

3

; and Tarik Hadid, MD, MS, MPH1

BACKGROUND: Cardiopulmonary arrest is known to have a poor prognosis, further worsened by preexisting comorbidities. With
improved treatment, the prevalence of metastatic cancers is rapidly increasing; however, the outcomes of in-hospital cardiopulmonary
resuscitation (ICPR) remain to be well described. This study examines the epidemiology, associations, and outcomes of ICPR in these
patients. METHODS: This is a retrospective cohort analysis of the Nationwide Inpatient Sample database (2012-2014) including patients aged ≥18 years with metastatic cancers. Primary outcome was inpatient mortality following ICPR. Factors associated with the
primary outcome were analyzed using univariate/multivariate logistic regression analysis. RESULTS: Among all admissions with metastatic cancers (n = 5,500,684), 0.47% (n = 26,070) received ICPR. Inpatient mortality was 81.77% (n = 8905) versus 68.90% among those
without metastatic solid cancers and receiving ICPR. Inpatient palliative care encounter was documented in 18.95% of patients with
metastatic cancer who received ICPR. On multivariate logistic regression, some of the notable factors associated with higher mortality
included being of African American or Hispanic race and hospital admission over the weekend. Factors associated with lower mortality included female sex, elective admission, and head and neck as the primary site. Admissions with ICPR were associated with higher
mean total charge of hospitalization (by $48,670) compared with admissions without ICPR. Of those who survived ICPR, 43.82% were
transferred to another facility after discharge. CONCLUSIONS: Among adult patients with metastatic solid cancers having ICPR, 81.8%
died within the same hospital admission. Race and admission type predicted mortality. Despite known poor prognosis, only a minority
had palliative care. Cancer 2021;0:1-10. © 2021 American Cancer Society.
LAY SUMMARY:
• Cardiopulmonary resuscitation during hospitalization for patients who have metastatic cancer has a very poor outcome with a mortality rate of 81.77%.
• Inpatient cardiopulmonary resuscitation in these patients is also associated with a significantly higher cost of care, longer length of
stay, and high rate of transfer to a different health care facility upon discharge.
• Knowledge of these outcomes is helpful in discussing the pros and cons of pursuing aggressive resuscitative interventions with
patients and families.
KEYWORDS: cancer, cardiopulmonary resuscitation (CPR), end-of-life care, health care use, metastatic malignancy, palliative service,
resuscitation.

INTRODUCTION
The use of inpatient cardiopulmonary resuscitation (ICPR) has increased over the past few decades. Because of
multiple quality initiatives and an algorithm-based approach to resuscitation following inpatient cardiac arrest, the
outcomes have also improved. The prevalence of metastatic solid cancers is at an all-time high because of rising
incidence and improved treatment modalities for all malignancies, including in the metastatic setting. There is an
intersection between older age and greater number of comorbidities in patients with metastatic malignancy leading
to increased health care use and multiple encounters with the health care system, especially closer to the end of life.
With improved outcomes for metastatic malignancy, the goals and expectations of physicians, patients, and families
have shifted, with a greater emphasis on aggressive care. There is a poor understanding of the actual outcomes in patients with metastatic solid cancers who receive ICPR and aggressive interventions. This is all the more important in
current times, with the availability of multiple treatment options for cancers and the development of ever-improving
technology for critical care interventions. In a recent study, 14% of patients who had in-hospital arrest also had
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advanced cancer.1 This population had a lower survival
rate compared with those without a diagnosis of advanced cancer. Also, they had their code status changed
more frequently to Do Not Resuscitate within 48 hours
of return of spontaneous circulation.
In our study, we analyzed the National Inpatient
Sample (NIS) database to estimate the incidence, outcomes, and length of stay related to CPR during the hospitalization of patients with metastatic solid malignancies.
NIS is the largest public database of hospital admissions
in the United States, developed for the Healthcare Cost
and Utilization Project (HCUP). The large sample size
of this database makes it particularly suitable to assess
outcomes across different hospital settings and patient
demographics.
MATERIALS AND METHODS
Data Source

The NIS was queried to analyze data from January
2012 to December 2014. The NIS is the largest publicly available all-payer inpatient health care database
in the United States; it was developed through a federal, state, and industry partnership sponsored by the
Agency for Healthcare Research and Quality. The NIS
is comprised of a random 20% sample of all inpatient
hospitalizations from 46 states in the United States. It
contains data from more than 7 million hospital stays
each year and can be used to estimate the delivery of
approximately 97% of all US inpatient care. Weighted,
the database has data on more than 35 million annual
hospital admissions nationally.2 This is a publicly available database and contains de-identified patient data;
hence, this study was exempt from institutional review
board approval. The NIS data are organized such that
each observation in the sample represents a unique hospitalization with information on more than 100 clinical
characteristics, including patient demographics (including age, sex, race, median income for zip code), hospital characteristics (including ownership, size, teaching
status, census region and division), and primary and up
to 29 secondary diagnoses, as well as 15 procedures as
administrative codes, diagnosis-related group codes for
disease severity, discharge status and disposition, total
charges, and length of stay.
Study Population and Methodology

We identified all hospitalizations among adult patients
(aged ≥18 years) with an International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9-CM)
2

primary or secondary procedure code for in-hospital CPR
(99.60, 99.63) to identify the adult patients who received
in-hospital CPR from 2012-2014. These codes have been
used in prior studies to identify patients receiving inhospital CPR. We then excluded patients who had a
primary diagnosis of cardiopulmonary arrest using the
ICD-9-CM diagnosis code 427.5 because these patients
may have experienced an out-of-hospital cardiac arrest.3
To allow a comparison between patients with and
without metastatic solid cancers, we defined the group
with metastatic solid cancer from our cohort using the
relevant ICD-9-CM diagnosis codes. The control group
consisted of those without metastatic solid cancers, including patients with a history of cancer and early-stage
cancer. We made our best attempt to adhere to the NIS
analysis guidelines recommended by the HCPU and
Khera et al.4 All the ICD-9 CM codes used for this
study are listed in the supporting information. No major
changes in the NIS sampling methodology occurred
during the study period.
Outcomes

The primary outcome was to compare inpatient mortality following ICPR (survival to hospital discharge) in patients with metastatic solid cancer versus those without
metastatic solid cancer. Secondary outcomes included
comparison between the above-described groups in terms
of length of stay and total charge of hospitalization.
Among those who survived, the discharge rate to home
versus a different nonacute care facility (nursing home or
rehabilitation facility) was also compared. In addition,
we also obtained patient characteristics (including age,
gender, race, insurance coverage, zip code income quartile as a surrogate for socioeconomic status, and Charlson
Comorbidity Index score) and hospital-level characteristics (including hospital size, teaching status, and urban or
rural location).
Statistical Analysis

All statistical analyses were performed using Stata IC
version 15.1 (Stata Corp). Appropriate survey procedures were used to maintain integrity of NIS data. We
performed a survey-weighted analysis using the SVY
command to account for stratification and clustering
of the NIS data. To compare baseline characteristics,
we used the χ2 test for categorical variables and t test
for continuous variables. The length of stay was standardized for age, sex, race, and hospital characteristics
using multivariate logistic regression. The predictors of
inpatient mortality were examined using a multivariate
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Figure 1. Consolidated standards of reporting trials (CONSORT)
diagram of patients included in the analysis. ICPR indicates inhospital cardiopulmonary resuscitation.

regression model that was standardized for all demographic and hospital characteristics that differed on
the univariate logistic regression. Mechanical invasive
ventilation was used as a surrogate for use of critical
care services. A multivariate logistic regression model
was built to determine predictors of inpatient mortality.
Missing values of any variable were excluded from the
final regression model. All P values were 2-sided with
.05 as the threshold for statistical significance.
RESULTS
From 2012-2014, there were 107,441,456 hospitalizations, of which 5.12% (n = 5,500,684) were of patients
with metastatic solid cancers. Of those with metastatic
solid cancer, 0.47% (n = 26,070) received ICPR (Fig. 1).
ICPR in the entire study population was documented
among 315,085 admissions from 2012-2014. Of these,
8.27% (n = 26,070) had metastatic solid cancer. Table 1
shows the comparison of baseline characteristics of patients with metastatic solid cancer who received ICPR
versus those who did not. Table 2 compares the baseline
characteristics of patients who underwent ICPR based on
the presence or absence of metastatic solid malignancy.
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Same Admission Mortality Among Those With
Metastatic Solid Cancer Receiving ICPR

There was a significant difference noted based on primary site
of malignancy (Table 3). Head and neck primary cancer had
the lowest mortality (62.81% of 390 who received ICPR)
compared with other primary sites (gastrointestinal, 83.69%;
lung, 80.99%; breast, 82.93%; genitourinary, 82.56%)
and this difference was significant (χ2 P value < .001).
The proportion of those who died was lower in White
(79.07%) compared with African American (86.40%) and
Hispanic (85.89%) patients (χ2 P value < .001). Based
on insurance status, mortality was documented among
80.31% of Medicare beneficiaries, 83.69% of Medicaid
beneficiaries, 83.27% of those with private insurance, and
86.36% of those who were self-pay; χ2 P value < .001.
In contradiction to expectations, younger patients
(aged 18-49 years) had worse mortality (89.31%) compared with age groups 50-64 years (80.36%) and ≥65
years (81.18%); χ2 P value < .001. Those with elective
admissions had lower mortality (72.06%) compared with
nonelective admissions (82.95%); χ2 P value < .001. A
higher proportion of patients admitted over the weekend died (85.95%) compared with those admitted on
weekdays (80.99%); χ2 P value < .001. There was no
difference in mortality by sex, urban or rural location of
hospital, teaching or nonteaching status of hospital, and
median household income quartile of patient’s zip code.
Disposition outcomes

Among the 1985 patients with metastatic solid cancer who
survived ICPR, 43.82% were transferred to a different health
facility at discharge. These included nursing homes and subacute rehabilitation and inpatient rehabilitation units.
Documented palliative care encounter

When we compared the use of palliative care services
among patients with metastatic cancer undergoing ICPR
based on presence or absence of comorbidities (congestive
heart failure, cerebrovascular accident, dementia, diabetes
mellitus, chronic kidney disease, chronic liver disease), no
statistically significant differences were noted.
Factors Associated With Receipt of ICPR in
Patients With Metastatic Solid Cancer

After adjusting for various factors including patient
demographics, comorbidities, and hospital factors, we
found that the odds of receiving ICPR was higher among
patients with metastatic malignancy who had the following characteristics (Table 4): nonelective admissions,
male patients, African American and Hispanic patients
3
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TABLE 1. Baseline Characteristics of Patients With Metastatic Cancer by Receipt of Inpatient
Cardiopulmonary Resuscitation
Patients n = 5,500,684

No ICPR (n = 5,474,614),
No. (%)

Age category, y
≥18-≤49
≥50-≤64
≥65
Sex
Female
Ethnicity
White
African American
Hispanic
Died during the hospitalization
Primary site of malignancy
Head and neck
Gastrointestinal
Lung (chest)
Breast
Genitourinary
Other
Comorbidities
Congestive heart failure
Cerebrovascular accident
Dementia
Chronic obstructive pulmonary disease
Diabetes mellitus with complications
Renal disease
Moderate-to-severe liver disease
Severe protein-energy malnutrition
Admission type
Admitted over the weekend
Nonelective admission
Aggressive interventions during admission
Hemodialysis during admission
Mechanical ventilation during admission
Cardiac revascularization during admission
Encounter with palliative care during admission
Transfer in
Not transferred in (admitted from home)
Transferred in from different acute care hospital
Transferred in from another type of health facility
Transfer out (upon discharge)
Not a transfer
Transferred out to a different acute care hospital
Transferred out to another type of health facility
Teaching hospital
Hospital size by number of beds
Small
Medium
Large
Insurance type
Medicare
Medicaid
Private insurance
Self-pay
Median household income national quartile for
patient zip code
0-25th percentile
26th-50th percentile
51st-75th percentile
76th-100th percentile

Received ICPR (n = 26,070),
No. (%)

Pearson χ2 P
.000

252,890 (12.60)
711,080 (35.44)
1,042,600 (51.96)

1170 (10.74)
3795 (34.83)
5930 (54.43)

1,019,930 (50.83)

4825 (44.29)

1,364,200 (71.68)
271,400 (14.26)
147,870 (7.77)
155,295 (7.74)

6285 (59.43)
2795 (26.43)
780 (7.38)
8905 (81.77)

50,650 (2.52)
606,895 (30.25)
547,230 (27.27)
224,145 (11.17)
453,660 (22.61)
123,990 (6.18)

390 (3.58)
3035 (27.86)
3820 (35.06)
1055 (9.68)
2065 (18.95)
530 (4.86)

161,555 (8.05)
87,420 (4.36)
4550 (0.23)
459,205 (22.89)
38,490 (1.92)
211,810 (10.56)
41,095 (2.05)
77,620 (3.87)

1925 (17.67)
680 (6.24)
30 (0.28)
3125 (28.68)
285 (2.62)
1565 (14.36)
450 (4.13)
760 (6.98)

.000
.000
.288
.000
.000
.000
.000
.000

361,025 (17.99)
1,521,580 (76.11)

2365 (21.71)
9625 (88.63)

.000
.000

24,625 (1.23)
67,185 (3.35)
10,290 (0.51)
273,770 (13.64)

690 (6.33)
8030 (73.70)
315 (2.89)
2065 (18.95)

.000
.000
.000
.000
.000

1,852,910 (92.77)
103,780 (5.20)
40,550 (2.03)

9680 (89.18)
775 (7.14)
400 (3.68)

1,603,795 (79.95)
42,430 (2.12)
359,800 (17.94)
1,260,780 (62.83)

9850 (90.45)
170 (1.56)
870 (7.99)
6765 (62.09)

269,960 (13.45)
484,395 (24.14)
1,252,215 (62.41)

1425 (13.08)
3000 (27.54)
6470 (59.39)

1,047,175 (53.90)
242,105 (12.46)
597,810 (30.77)
55,745 (2.87)

6025 (56.47)
1625 (15.23)
2690 (25.21)
330 (3.09)

.000
.000

.000
.000

.000

.111
.000

.000

.000
531,035 (27.06)
499,575 (25.46)
474,685 (24.19)
457,165 (23.30)

3515 (33.02)
2475 (23.25)
2295 (21.56)
2360 (22.17)

Abbreviation: ICPR, in-hospital cardiopulmonary resuscitation.
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TABLE 2. Baseline Characteristics of Patients Who Underwent Inpatient Cardiopulmonary Resuscitation by
Presence or Absence of Metastatic Solid Malignancy
Patients Who Underwent
ICPR n = 315,085
Age category, y
≥18-≤49
≥50-≤64
≥65
Sex
Female
Ethnicity
White
African American
Hispanic
Died during the hospitalization
Comorbidities
Congestive heart failure
Cerebrovascular accident
Dementia
Chronic obstructive pulmonary
disease
Diabetes mellitus with complications
Renal disease
Moderate-to-severe liver disease
Severe protein-energy malnutrition
Aggressive interventions during
admission
Hemodialysis during admission
Mechanical ventilation during
admission
Cardiac revascularization during
admission
Admission type
Admitted over the weekend
Nonelective admission
Encounter with palliative care during
admission
Transfer in (prior to admission)
Not transferred in (admitted from
home)
Transferred in from different acute
care hospital
Transferred in from another type of
health facility
Transfer out (upon discharge)
Not a transfer
Transferred out to a different acute
care hospital
Transferred out to another type of
health facility
Teaching hospital
Hospital size by number of beds
Small
Medium
Large
Insurance type
Medicare
Medicaid
Private insurance
Self-pay
Median household income national
quartile for patient zip code
0-25th percentile
26th-50th percentile
51st-75th percentile
76th-100th percentile

Patients Without Solid Metastatic Cancer
(n = 289,015), No. (%)

Patients With Solid Metastatic Cancer
(n = 26,070), No. (%)

Pearson χ2 P
.000

42,160 (13.86)
83,710 (27.52)
178,320 (58.62)

1170 (10.74)
3795 (34.83)
5930 (54.43)

133,000 (43.73)

4825 (44.29)

184,370 (63.28)
59,125 (20.29)
28,385 (9.74)
209,540 (68.90)

6285 (59.43)
2795 (26.43)
780 (7.38)
8905 (81.77)

.000

117,245 (38.54)
32,375 (10.64)
2135 (0.70)
85,395 (28.07)

1925 (17.67)
680 (6.24)
30 (0.28)
3125 (28.68)

.000
.000
.000
.164

22,455 (7.38)
98,080 (32.24)
11,060 (3.64)
10,470 (3.44)

285 (2.62)
1565 (14.36)
450 (4.13)
760 (6.98)

.000
.000
.007
.000

41,950 (13.79)
220,970 (72.64)

690 (6.33)
8030 (73.70)

.000
.015

39,730 (13.06)

315 (2.89)

.000

74,400 (24.46)
272,740 (90.00)
33,630 (11.06)

2365 (21.71)
9625 (88.63)
2065 (18.95)

.000
.000
.000

262,365 (86.72)

9680 (89.18)

26,560 (8.78)

775 (7.14)

13,615 (4.50)

400 (3.68)

250,945 (82.51)
11,595 (3.81)

9850 (90.45)
170 (1.56)

41,595 (13.68)

870 (7.99)

173,515 (57.04)

6765 (62.09)

37,380 (12.29)
85,610 (28.14)
181,200 (59.57)

1425 (13.08)
3000 (27.54)
6470

195,530 (66.17)
34,280 (11.60)
50,115 (16.96)
15,575 (5.27)

6025 (56.47)
1625 (15.23)
2690 (25.21)
330 (3.09)

.250
.000

.000

.000

.000
.034

.000

.000
97,895 (32.97)
76,630 (25.81)
67,170 (22.62)
55,260 (18.61)

3515 (33.02)
2475 (23.25)
2295 (21.56)
2360 (22.17)

Abbreviation: ICPR, in-hospital cardiopulmonary resuscitation.
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TABLE 3. ICPR Mortality by Primary Site of Tumor
Primary Site: Metastatic Solid
Cancer
Head and neck
Gastrointestinal
Lung (chest)
Breast
Genitourinary
Other

No. of Cases

Proportion of Patients
Who Received ICPR (%)

Mortality Following
ICPR (%)

390
3035
3815
1055
2065
530

0.76
0.49
0.69
0.46
0.45
0.42

62.81
83.69
80.99
82.94
82.57
84.91

Abbreviation: ICPR, in-hospital cardiopulmonary resuscitation.

TABLE 4. Factors Associated With Receipt of ICPR Among Patients With Metastatic Solid Malignancy
Odds of ICPR Among Hospitalized Patients With Metastatic Solid Cancer
Age, y
Females vs males
Ethnicity
African Americans vs Whites
Hispanics vs Whites
Admission type
Elective vs nonelective admission
Weekend vs weekday admission
Site of primary malignancy
Gastrointestinal vs head and neck
Lung (chest) vs head and neck
Breast vs head and neck
Genitourinary vs head and neck
Others vs head and neck
Teaching vs nonteaching hospital
Hospital size by number of beds
Medium vs small hospitals
Large vs small hospitals
Insurance type
Medicaid vs Medicare
Private insurance vs Medicare
Self-pay vs Medicare
Transfer in (prior to admission)
Transferred in from different acute care hospital vs not transferred in
Transferred in from another type of health facility vs not transferred in
Comorbidities
Congestive heart failure: present vs absent
Cerebrovascular accident: present vs absent
Chronic obstructive pulmonary disease: present vs absent
Moderate-to-severe liver disease: present vs absent
Severe protein energy malnutrition: present vs absent
Diabetes mellitus with complications: present vs absent
Renal disease: present vs absent
Median household income national quartile for patient zip code
26th-50th percentile vs 0-25th percentile
51st-75th percentile vs 0-25th percentile
76th-100th percentile vs 0-25th percentile

Multivariate Adjusted OR (95% CI)

P

1.000 (0.998-1.002)
0.796 (0.763-0.831)

.869
.000

2.195 (2.089-2.305)
1.214 (1.121-1.314)

.000
.000

0.518 (0.486-0.552)
1.073 (1.023-1.126)

.000
.004

0.518 (0.464-0.578)
0.702 (0.629-0.783)
0.567 (0.50-0.642)
0.467 (0.417-0.523)
0.558 (0.487-0.640)

.000
.000
.000
.000
.000

0.936 (0.897-0.976)

.002

1.102 (1.032-1.178)
0.927 (0.872-0.985)

.004
.014

1.098 (1.025-1.176)
0.958 (0.906-1.014)
1.061 (0.941-1.196)

.008
.137
.334

1.522 (1.409-1.643)
1.647 (1.481-1.832)

.000
.000

2.183 (2.068-2.305)
1.225 (1.129-1.329)
1.115 (1.064-1.169)
1.961 (1.774-2.169)
1.673 (1.548-1.807)
1.023 (0.90-1.163)
1.109 (1.046-1.177)

.000
.000
.000
.000
.000
.726
.001

0.894 (0.847-0.944)
0.890 (0.841-0.941)
0.996 (0.941-1.054)

.000
.000
.889

Abbreviations: ICPR, in-hospital cardiopulmonary resuscitation; OR, odds ratio.

(vs White), patients in nonteaching hospitals, small hospitals (vs medium- or large-sized hospitals by bed number), Medicare beneficiaries (vs Medicaid beneficiaries
or those with private insurance), weekend admissions,
transferred from a different acute care facility, head and
neck malignancy (vs other primary site), presence of comorbidities (congestive heart failure, cerebrovascular accident, chronic kidney disease, chronic kidney disease,
moderate-to-severe liver disease, severe protein-energy
6

malnutrition), and belonging to the lowest income quartile (vs 26th-50th percentile and 51th-75th percentile).
Factors Associated With Same Admission
Mortality Among Patients With Metastatic Solid
Cancer Who Received ICPR

After adjusting for various factors including patient demographics, comorbidities, and hospital factors, we
found that the odds of same admission mortality among
Cancer  
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TABLE 5. Factors Associated With Same
Admission Mortality Among Patients With
Metastatic Solid Malignancy Who Received ICPR

TABLE 6. Comparative Outcomes of Patients
With Metastatic Malignancy Who Did and Did Not
Receive ICPR

Odds of Mortality Among Hospitalized
Metastatic Solid Cancer Patients Who
Underwent ICPR

Multivariate
Adjusted OR
(95% CI)

P

Solid Metastatic
Cancer

Age, y
Females vs males
Ethnicity
African Americans vs Whites
Hispanics vs Whites
Comorbidities
Congestive heart failure: present vs
absent
Cerebrovascular accident: present vs
absent
Dementia: present vs absent
Chronic obstructive pulmonary disease:
present vs absent
Moderate to severe liver disease: present
vs absent
Site of primary malignancy
Gastrointestinal vs head and neck
Lung (chest) vs head and neck
Breast vs head and neck
Genitourinary vs head and neck
Others vs head and neck
Admission type
Elective vs nonelective admission
Weekend vs weekday admission
Hospital size by number of beds
Medium vs small hospitals
Large vs small hospitals
Insurance type
Medicaid vs Medicare
Private insurance vs Medicare
Self-pay vs Medicare
Transfer in (prior to admission)
Transferred in from different acute care
hospital vs not transferred in
Transferred in from another type of health
facility vs not transferred in

1.001 (0.996-1.006)
0.803 (0.72-0.896)

.667
.000

1.515 (1.329-1.727)
1.308 (1.05-1.629)

.000
.017

0.741 (0.651-0.844)

.000

0.575 (0.475-0.696)

.000

0.001 (0.297-0.141)
0.778 (0.691-0.875)

.001
.000

1.934 (1.355-2.761)

.000

2.866 (2.257-3.638)
2.647 (2.097-3.342)
2.895 (2.177-3.851)
3.064 (2.391-3.928)
3.847 (2.762-5.358)

.000
.000
.000
.000
.000

0.582 (0.503-0.675)
1.138 (0.998-1.298)

.000
.053

1.181 (0.999-1.398)
1.19 (1.022-1.387)

.052
.025

1.237 (1.036-1.478)
1.152 (0.996-1.332)
1.43 (1.02-2.004)

.019
.057
.038

1.118 (0.908-1.377)

.292

2.301 (1.605-3.297)

.000

Abbreviations: ICPR, in-hospital cardiopulmonary resuscitation; OR, odds ratio.

patients with metastatic malignancy who received ICPR
was higher among those with the following characteristics
(Table 5): nonelective admission, male, African American
and Hispanic patients (vs White), teaching hospital,
medium- and large-sized hospitals (vs small hospitals by
bed number), Medicaid beneficiaries and those with private
insurance (vs Medicare), weekend admissions, transferred
in from a different acute care hospital, gastrointestinal/
lung/breast/genitourinary malignancies (vs head and neck
primary cancer site), presence of moderate-to-severe liver
disease, and absence of congestive heart failure, cerebrovascular accident, dementia, and chronic kidney disease.
Admission characteristics

The mean length of stay among patients with metastatic
solid cancer was approximately 2 days longer for those
who received ICPR compared with those who did not.
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Length of stay,
mean (SD), d
Total charge for
hospitalization,
mean (SD)

Did Not Receive
ICPR

Received ICPR

t Test P

6.46
(6.74)
$57,507.28
($76,930.72)

8.46
(10.89)
$106,176.81
($154,104.88)

.000
.000

Abbreviation: ICPR, in-hospital cardiopulmonary resuscitation.

The mean total charge for hospitalization was approximately $48,670 higher among those who received ICPR
(Table 6). This increase in hospitalization charge could be
accounted for by both increased length of stay and use of
intensive care services and interventions. The mean time
to ICPR among these patients was 3.28 days from admission. The most common reasons for admission among
those patients with metastatic solid cancer who received
ICPR and died during the same hospitalization—in decreasing order of frequency—included sepsis (17.29%),
acute respiratory failure, malignant neoplasm of bronchus and lung, pneumonia, pulmonary embolism, and
infarction.
DISCUSSION
We found that the mortality rate in same admission after
ICPR is significantly higher in those who have metastatic solid cancer compared with those who do not. It is
important to keep in mind that the no metastatic solid
cancer group does include those with malignancy that is
not metastatic. This means that despite the comparison
group including a diagnosis of malignancy, the mortality is still remarkably different (~82% for metastatic
solid cancer and ~69% for those without metastatic
solid cancer). The odds of mortality following ICPR in
patients with metastatic solid cancer was roughly 50%
and 30% higher in African Americans and Hispanics,
respectively, when compared with Whites after adjusting for multiple factors including socioeconomic status
and comorbidities. Possible confounders (not recorded
in the database) that could account for this observation include the extent of metastatic disease, differences
in disease biology/aggressiveness, performance status,
treatment history, and differences in access to health
care. The odds of ICPR were comparatively not higher
in African American patients than in White patients. But
the odds of ICPR were higher by approximately 20% in
Hispanic patients in comparison with White patients.
One of the explanations for these findings could be the
7
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cultural differences in relation to goals of care and code
status decisions. In a single-institution retrospective
study including patients of 7 ethnicities who underwent
inpatient palliative consultation, health care use in the
last 3 months of life varied widely between groups. It
was highest for African American and Hispanic patients
with ≥3 emergency room visits in 30% and 25%, respectively. Also, the median time elapsed from palliative
care encounter to hospice referral was 4 days for White
and 26.5 days for African American patients.5 These
findings highlight the complex interplay of various factors, some of which are hard to quantify and ultimately
lead to variations in outcomes.
Head and neck cancers, despite having 30% to 50%
higher odds of ICPR when compared with other tumor
types, had a surprisingly much lower odds of mortality following ICPR. Although the higher odds of ICPR can be
explained possibly by the high risk of sepsis from frequent
aspirations, the much lower mortality could be caused
by selection bias. Among all cancer subtypes, head and
neck cancer was found to be associated with the shortest
time interval between a diagnosis of advanced disease and
palliative care consultation (2.9 months) in a large retrospective study from Brazil.6 It is therefore possible that
decisions regarding goals of care and code status for the
“sicker” patient with head and neck cancer had already
been addressed before admission and the cohort receiving ICPR was relatively less sick. In addition, admission
over the weekend was associated with 14% higher odds of
mortality when compared with weekdays; this could be a
reflection of logistical issues over weekends in our hospitals across the nation.
Quality of life is an important outcome in cancer
care, especially for patients with incurable metastatic solid
cancers. Being at home with family and in familiar surroundings is often expressed as a goal when discussing
care strategies and optimal location of care. We noted in
this study that 41% of metastatic solid cancer cases who
survived the ICPR were transferred to a different facility
at discharge. Contrast this with those who did not received ICPR, where only 18.3% needed to be transferred
to a different facility at discharge. Different facility here
denotes nursing home, rehabilitation center, and other
facilities excluding acute care hospitals. Although this
would presumably affect the quality of life of patients,
it also increases the health care use and total cost of care
among patients with metastatic malignancy. We also
noted longer length of stay and higher mean total charge
of hospitalization among those with metastatic solid cancer receiving ICPR.
8

A population-based cohort study from Taiwan,7
which studied 3446 patients with metastatic malignancy,
found that there was a very low rate of survival to discharge after cardiopulmonary resuscitation (~7.2%).
Even among those who survived to discharge, only 10.1%
received anticancer therapy, whereas the median postdischarge survival rate was 22 days. This puts in perspective the gains achieved by resuscitation of patients with
metastatic malignancy. Even though resuscitation science
has made many strides in the past few years, we need to
re-evaluate the burden placed on the patients, relatives,
and the health care system for very modest to no gain
in quality and length of life with very few patients eventually receiving meaningful cancer–directed therapy. In
addition to quality of life, equally important and much
more difficult to quantify is the “quality of the dying experience.” Based on responses gathered from caregivers,
positive ratings in terms of quality of death were highest
for home deaths, perhaps because they were associated
with fewer complications and/or a more extensive support network at home.8 Also, in practice we have seen that
the quality of death significantly deteriorates among those
patients who do not survive CPR and aggressive interventions. Although the definition of medical futility (as
discussed by Schneiderman9) includes therapy that offers
<1% chance of survival, this does not take into account
other end points that we have previously discussed.
There are several studies that show the benefits of
involving a palliative care team in the care of patients with
malignancy. Despite this, there has been an increasing
trend of offering and implementing aggressive cancer–
directed therapy near the end of life. Primary physicians
and oncologists are not always well trained in end-of-life
care and the discussion of goals of therapy and death.
There are many barriers to such a discussion, and this is
an area of ongoing study. There have been multiple randomized prospective studies that have shown that the
involvement of specialty palliative services leads to significant improvement in the quality of life and a decrease in
the use of futile and aggressive end-of-life care, along with
a survival benefit.10 In our study of those with metastatic
solid cancer and receiving ICPR between 2012 and 2014,
we did not see a substantial increase in the proportion
of patients with a documented palliative care encounter
over the years. It should be noted that documentation of a
palliative care encounter does not include use of palliative
care services before admission and hence may be subject
to a selection bias. It is also subject to documentation
bias, because occasionally palliative services are not coded
for. Despite not being the primary goal of treatment, cost
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of care,11 and length of stay,12 admissions to the intensive care unit have been found to be lower in those who
are evaluated and treated by a specialty palliative team.
A single-center study showed that the most significant
barriers to discussing goals of care as perceived by oncology providers were family members’ difficulty accepting
poor prognosis, disagreement among family members,
difficulty understanding the limitations of life-sustaining
treatments, and the lack of patients’ capacity to make decisions.13 Through our study, we hope to address, to some
extent, the difficulty in understanding the limitations of
life-sustaining treatments. Being able to provide actual
probabilities of survival after ICPR in a patient with metastatic solid cancer, along with insight into the quality of
life and death after resuscitation, will hopefully help family members to make more informed decisions.
Surprisingly, we noted that patients with metastatic
solid cancer receiving ICPR who had an inpatient palliative care consultation ended up with a longer length of
stay and higher total charge for admission. We previously
discussed evidence that palliative care decreases cost of
care, but that is true for early involvement of palliative
care services, usually in the outpatient setting (information not available in our database). A possible explanation
for this could be late involvement of palliative care services in the course of hospitalization, especially at a time
when end of life is imminent or at the time of death, thus
leading to a selection bias. This is a phenomenon that is
frequently seen in clinical practice too. Our observation
agrees with a study by Earle et al,14 which reported that
among those who receive hospice care, an increasing proportion had such care initiated in the last 3 days of life.
There has been excellent ongoing work and tools
developed to better stratify patients who will not benefit from ICPR, one of which is the Good Outcome
Following Attempted Resuscitation (GO-FAR) score.15
One of the variables included in the score is the presence
of metastatic malignancy. The use of such simple clinical
scores in a discussion of goals of care and resuscitation
status with patients integrated with patient and provider
awareness of low survival as described in many studies,
including ours, will be instrumental in informing endof-life decisions. Although we cannot say that any ICPR
is fruitless in patients with metastatic malignancy, we encourage patients and providers to tailor code status discussion and decisions based on a better understanding of
the expected outcomes and anticipated benefit.
This study has several limitations based on its retrospective design using an administrative database. As
expected from an administrative database, there may be
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coding and data entry errors in the NIS database. The
NIS database only contains in-hospital data, thus survival
and complications occurring after discharge are largely
unknown. We do not have quality-of-life indicators
available from the patients or long-term survival data.
Although the Charlson Comorbidity Index was used, the
ability to accurately control for different baseline comorbidities is limited when administrative data are used. The
cost analyzed was in-hospital and did not provide a reflection of out-of-hospital costs and costs after transfer to
rehabilitation services or nursing home. A larger registry
trial, which provides data regarding long-term survival
outcomes of patients with metastatic malignancy who
receive ICPR, would provide us with invaluable information that we can use while weighing clinical decisions and
counseling our patients on expected outcomes. Palliative
care consultation, though coded for inclusion in the database, may be an underestimation because if the physician providing such care is not palliative board certified,
this would not be reflected in an administrative database.
Regardless, this comprehensive large sample-size study
using a national, regionally diverse, and all-payer database
provides a real-world picture of inpatient cardiopulmonary resuscitation in hospitalized patients with metastatic
solid cancer across the Unites States.
In this era of rapid evolution of treatments and frequent approval of new therapies—though maintaining
optimism is healthy—we must understand the global picture of expected outcomes while discussing the goals of
care with our patients with metastatic solid cancers. We
hope this study will add to the existing knowledge base
and aid in providing patients with accurate information
when they are deciding on code status and goals of care.
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